Here, the authors review how cancer and cancer therapies interact with metabolism at the cellular and systemic levels. An overview of metabolomics is provided with a focus on currently available technologies and how they have been applied in the clinical and translational research setting. The ...
Amino acid metabolism, which can affect cancer cell status and systemic metabolism through energy metabolism and signal transduction, is deregulated in PDAC [47]. Glutamine is the most abundant nonessential amino acid in the human body [48]. Cancer cells can convert glutamine into lactic acid, pa...
Targeting myeloid cells with immunotherapy was discussed at length during the 2021 China Cancer Immunotherapy workshop in Beijing, the sixth annual conference organized by the Chinese American Hematologist and Oncologist Network (CAHON), China Center for Food and Drug International Exchange (CCFDIE), Chi...
Bisphosphonates, bone, and breast cancer recurrence. Lancet 386, 1319–1320 (2015). Article PubMed Google Scholar Guarneri, V., Barbieri, E., Dieci, M. V., Piacentini, F. & Conte, P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat. Rev. 36, ...
SULT2B1: a novel therapeutic target in colorectal cancer via modulation of AKT/PKM2-mediated glycolysis and proliferation Sulfotransferase family 2B member 1 (SULT2B1) is involved in regulating cell proliferation, migration and metabolism. However, there is still dispute regarding whether SULT2B1 acts ...
(NSAI) in premenopausal women with HR+/HER2− advanced breast cancer. Patients will be randomly assigned in a 1:1 ratio to two treatment arms: ribociclib or placebo plus goserelin and tamoxifen/NSAI. Furthermore, clinical trials of ribociclib in combination with targeted therapies and/or ...
Brufsky, A. & Mathew, A. Bisphosphonates, bone, and breast cancer recurrence.Lancet386, 1319–1320 (2015). ArticlePubMedGoogle Scholar Guarneri, V., Barbieri, E., Dieci, M. V., Piacentini, F. & Conte, P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.Cance...
Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers A (2012) Eastern Canadian colorectal cancer consensus confer- ence: application of new modalities of staging and treatment of gastrointestinal cancers. Cur......
Cancer stem cells (CSCs) or tumor-initiating cells (TICs) represent a small population of cancer cells with self-renewal and tumor-initiating properties. Unlike the bulk of tumor cells, CSCs or TICs are refractory to traditional therapy and are responsib
5,6 In a word, cancer immunotherapy has experienced remarkable advances since the clinical success of immune checkpoint blockade and CAR-T-cell therapies in recent years. It has become an innovative treatment and a powerful clinical strategy due to its incomparable advantages over traditional ...